Nimbus Therapeutics (FKA Nimbus Discovery), a Cambridge, MA-based biotechnology company, completed a $43m Series B financing.
The round was led by Pfizer Venture Investments and Lightstone Ventures with participation from Series A investors Atlas Venture, SR One, Lilly Ventures and Bill Gates.
The company intends to use the funds to advance its lead program, an Acetyl CoA Carboxylase (ACC) inhibitor, into clinical development and preclinical programs of novel small molecules including those for IRAK4, Tyk2, KRas and other medically-important targets.
Led by Donald “Don” Nicholson, Ph.D., chief executive officer, Nimbus is a biotechnology company which leverages computational chemistry to design innovative medicines for the treatment of metabolic diseases, cancer and immune-inflammatory disorders. The company, which works in coordination with its co-founding partner, Schrödinger, and a network of partners and collaborators, is advancing ACC in Non-alcoholic Steatohepatitis, or NASH, a serious condition that can lead to liver cirrhosis, often leading to transplant, and other complications including hepatocellular carcinoma, a liver cancer with high mortality rates.